Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02157324 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT02157324 · ClinicalTrials.gov record · last posted 2025-08-13

Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia

Name: Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia — clinical trial record (NCT02157324)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorAcerta Pharma BV

Started2014-08-18

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study is evaluating the safety and efficacy of the combined use of acalabrutinib and ACP-319, for the treatment of chronic lymphocytic leukemia (CLL)

Amendment record 28 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 28 times since 2014-06-04; most recent amendment 2025-08-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2015-11-05

Status change Recruiting→Active, Not Recruitingv8

2014-08-08

Status change Not Yet Recruiting→Recruitingv2

Trial Details

NCT Number	NCT02157324
Lead Sponsor	Acerta Pharma BV
Conditions	Chronic Lymphocytic Leukemia
Enrollment	12 participants
Start Date	2014-08-18
Primary Completion	2020-07-20 (estimated)
Study Completion	2026-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-08-13